Analyst cuts weigh
Fresh price target cuts and slower demand commentary after the Q3 report are pressing Alnylam lower in an orderly slide on normal volume.
Sources: https://www.benzinga.com/news/26/10/62730048/raymond-james-downgrades-alnylam-pharmaceuticals-outperform-lowers-price-target, https://seekingalpha.com/article/alnylam-pharmaceuticals-inc-2026-q3-results-earnings-
Previous verdicts for ALNY
- AI Search: Alnylam Falls Sharply as Truist Downgrade Weighs on Amvuttra Outlook — 2026-11-02
- AI Search: Alnylam Pharmaceuticals Sells Off Aggressively After Q3 Earnings — 2026-10-29
- AI Search: Alnylam Rises as Brezosiran Data Draws Favorable Investor Response — 2026-10-26
- AI Search: Alnylam slips modestly as profit-taking follows Alzheimer race coverage — 2026-10-21
- AI Search: UBS Trims ALNY Price Target, Stock Holds Slightly Higher — 2026-10-16
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works